TLPH (Talphera) Net Issuance of Preferred Stock : $0.00 Mil (TTM As of Mar. 2025)

View and export this data going back to 2011. Start your Free Trial

What is Talphera Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

Talphera's net issuance of preferred for the three months ended in Mar. 2025 was $0.00 Mil. The number is 0, which means that Talphera has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

Talphera's net issuance of preferred for the trailing twelve months (TTM) ended in Mar. 2025 was $0.00 Mil.

Talphera Net Issuance of Preferred Stock Historical Data

The historical data trend for Talphera's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Talphera Net Issuance of Preferred Stock Chart

Talphera Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Issuance of Preferred Stock

Get a 7-Day Free Trial

-0.08

Talphera Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Net Issuance of Preferred Stock	Get a 7-Day Free Trial															-	-	-	-	-

Talphera Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Talphera Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of Talphera's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Talphera Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Talphera Inc (NAS:TLPH) » Definitions » Net Issuance of Preferred Stock

Comparable Companies

Traded in Other Exchanges

R5XA:Germany R5XA:Germany

Address

1850 Gateway Drive, Suite 175, San Mateo, CA, USA, 94404

Website

https://www.talphera.com

Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.

Executives

Vincent J. Angotti	director, officer: Chief Executive Officer	C/O ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Raffi Asadorian	officer: Chief Financial Officer	C/O ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Pamela P Palmer	director, officer: Chief Medical Officer	C/O ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Jill Marie Broadfoot	director	3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Marina Bozilenko	director	C/O ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Adrian Adams	director	C/O AUXILIUM PHARMACEUTICALS, INC., 640 LEE ROAD, CHESTERBROOK PA 19355
Mark G Edwards	director	ALLOS THERAPEUTICS, INC., 11080 CIRCLEPOINT ROAD, SUITE 200, WESTMINSTER CO 80020
Badri N Dasu	officer: Chief Engineering Officer	C/O ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Lawrence G Hamel	officer: Chief Development Officer	C/O ACELRX PHARMACEUTICALS INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Mark A Wan	director, 10 percent owner	C/O THREE ARCH PARTNERS, 3200 ALPINE RD, PORTOLA VALLEY CA 94028
Three Arch Associates Iii Lp	10 percent owner	C/O THREE ARCH PARTNERS, 3200 ALPINE ROAD, PORTOLA VALLEY CA 94028
Wilfred E Jaeger	10 percent owner	C/O THREE ARCH PARTNERS, 3200 ALPINE RD, PORTOLA VALLEY CA 94028
Three Arch Partners Iii Lp	10 percent owner
Three Arch Partners Iv Lp	10 percent owner
Three Arch Associates Iv Lp	10 percent owner	3200 ALPINE ROAD, PORTOLA VALLEY CA 94028